Hypera S.A. (BVMF:HYPE3)

Market Cap	14.79B
Revenue (ttm)	6.97B
Net Income (ttm)	823.94M
Shares Out	632.94M
EPS (ttm)	1.29
PE Ratio	18.04
Forward PE	7.99
Dividend	1.17 (5.01%)
Ex-Dividend Date	Dec 29, 2025

Volume	894,400
Average Volume	3,017,295
Open	23.05
Previous Close	n/a
Day's Range	23.00 - 23.50
52-Week Range	17.61 - 28.87
Beta	0.25
RSI	42.65
Earnings Date	Feb 24, 2026

About Hypera

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, pleased, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, Luna, moon, Lydian, macrodantin, MaxSulid, Milgamma, Mioflex – A, Nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, Softalm, Tacroz, Tinodin, Umma, an...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1999
• Employees: 10,481
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: HYPE3

Financial Performance

In 2024, Hypera's revenue was 7.44 billion, a decrease of -5.97% compared to the previous year's 7.91 billion. Earnings were 1.34 billion, a decrease of -18.63%.